Syntara Limited has released a press release.
Pharmaxis Business Plan Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Quarterly Shareholder Update - September 2019
- FDA Provides Guidance on Bronchitol Approval Steps
- Pharmaxis Receives $6.2m R&D Tax Incentive
- Quarterly Shareholder Update - June 2019
- Pathway to US Bronchitol Approval Clarified in FDA Response
Later from Syntara
- Quarterly Shareholder Update - December 2019
- PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020
- Pharmaxis Quarterly Shareholder Update - March 2020
- Fourth Quarter Activity Report
- US$7 million Bronchitol Launch Milestone Brought Forward
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara